Mesuximide

Mesuximide
Clinical data
Trade names	Celontin
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a682028
Pregnancy; category	US: C (Risk not ruled out) ;
Routes of; administration	By mouth (capsules)
ATC code	N03AD03 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Metabolism	Hepatic (demethylation and glucuronidation)
Metabolites	N-desmethylmethosuximide
Elimination half-life	1.4–2.6 hours (mesuximide); 28–38 hours (active metabolite)
Excretion	Urine
Identifiers
	IUPAC name (RS)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione;
CAS Number	77-41-8 ;
PubChem CID	6476;
IUPHAR/BPS	7228;
DrugBank	DB05246 ;
ChemSpider	6231 ;
UNII	0G76K8X6C0;
KEGG	D00404 ;
ChEMBL	ChEMBL697 ;
CompTox Dashboard (EPA)	DTXSID5023293 ;
ECHA InfoCard	100.000.934
Chemical and physical data
Formula	C12H13NO2
Molar mass	203.237 g/mol g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES O=C2N(C(=O)CC2(c1ccccc1)C)C;
	InChI InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3 ; Key:AJXPJJZHWIXJCJ-UHFFFAOYSA-N ;
(what is this?) (verify)

Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]

Medical use

is indicated for the control of absence seizures that are refractory to other drugs.[2]

References

Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Archived from the original on April 22, 2005. Retrieved August 21, 2006.
Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014.
Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methosuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Petinutin-1] Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Archived from the original on April 22, 2005. Retrieved August 21, 2006.

[Celontin-2] Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014.

[3] Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methosuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.